Del Mar, California — October 16, 2025 — Leads & Copy — American Diversified Holdings Corporation (OTCID: ADHC) has announced a commitment from a prominent institutional investment fund for up to $5,000,000 in financing.
The funds will support the research and development of the GlucoGuard project and for general corporate purposes, as well as collaboration with DexCom, a Continuous Glucose Monitoring (CGM) development partner. The company said that the funds will launch ADHC into a new phase of enhanced valuation.
Following interactions with the ADHC Medical Advisory Board (MAB) and the Food and Drug Administration (FDA), a two-prong SLEEP STUDY was requested to address safety and efficacy concerns. Arete Bioscience and Dr. Kunal Sur PhD have presented a Scope of Work (SOW) proposal including “Use of Funds” in coordination with a sleep laboratory to meet the FDA’s requirements.
The FDA has positively reviewed the major components of the Breakthrough Device Application Designation related to the “UNMET NEED” and GlucoGuard’s potential to assist patients.
ADHC stated that they have advanced GlucoGuard toward FDA approval rapidly with minimal capital, driven by their team. The company concluded that preventing potentially life-threatening events during sleep would improve patients’ lives.
Contact: John Cacchioli, CEO American Diversified Holdings Corporation. Telephone: (212) 537-5900. Email: JC@American-Diversified.com
Social Media: Twitter: @ADHCManagement
Source: American Diversified Holdings Corporation
